Last update 01 Nov 2024
Zhejiang JinFang Pharmaceutical Co., Ltd.
Private Company|
2018|
Zhejiang Sheng, China
Last update 01 Nov 2024
Overview
Tags
Neoplasms
Respiratory Diseases
Immune System Diseases
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
一项评价GFH009联合泽布替尼治疗复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者安全性和有效性的单臂、开放、多中心Ib/II期临床试验
[Translation] A single-arm, open-label, multicenter Phase Ib/II clinical trial evaluating the safety and efficacy of GFH009 combined with zanubrutinib in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
一项评估GFH009在复发或难治的外周T细胞淋巴瘤患者中的有效性、安全性/耐受性和药代动力学的多中心、开放标签、Ib/II期临床研究
[Translation] A multicenter, open-label, Phase Ib/II clinical study evaluating the efficacy, safety/tolerability, and pharmacokinetics of GFH009 in patients with relapsed or refractory peripheral T-cell lymphoma
100 Clinical Results associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Zhejiang JinFang Pharmaceutical Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 07 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
5
1
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free